Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $146.00 short call and a strike $152.50 long call offers a potential 32.11% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $146.00 by expiration. The full premium credit of $1.58 would be kept by the premium seller. The risk of $4.92 would be incurred if the stock rose above the $152.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 36.19 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
EU agency accepts Sandoz application for pegfilgrastim biosimilar
Thu, 11 Feb 2016 06:30:24 GMT
Reuters – The European Medicines Agency (EMA) has accepted an application to review Sandoz's biosimilar to Amgen's EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on Thursday. Sandoz is seeking approval for the same indication as the reference product, it added in a statement.
Novartis And the Future Of Drug Pricing
Wed, 10 Feb 2016 21:25:00 GMT
Relypsa: This Biotech Just Released Stunning Data
Wed, 10 Feb 2016 18:55:08 GMT
Panel Recommends FDA Approval of Remicade Knockoff
Wed, 10 Feb 2016 14:51:54 GMT
Major Biotech Short Interest Continues to Be Mixed
Wed, 10 Feb 2016 13:40:01 GMT
Also on Market Tamer…
Follow Us on Facebook